On January 12, 2026, the European Commission granted marketing authorization for Biogen’s high-dose SPINRAZA regimen for 5q spinal muscular atrophy (SMA), representing 95% of SMA cases. The updated dosing comprises two 50 mg loading doses administered 14 days apart, followed by 28 mg maintenance doses every four months. Approval was supported by data from the Phase 2/3 DEVOTE study, which enrolled 145 participants across 42 sites. In the pivotal cohort of 75 treatment-naïve infants, the high-dose regimen produced a mean CHOP-INTEND improvement of +15.1 points versus –11.1 in a matched sham group (mean difference 26.19; p<0.0001). Transitioned patients (n=40) saw a mean Hammersmith Functional Motor Scale–Expanded gain of 1.8 points (SD 3.99) at Day 302. Adverse events were consistent with known safety profiles, with pneumonia and aspiration pneumonitis reported in ≥10% of high-dose patients and ≥5% above sham incidence. The regimen is now approved in the EU and Japan, and under FDA review with a decision expected by April 3, 2026.

During its session at the 44th Annual J.P. Morgan Healthcare Conference, Biogen outlined strategic priorities for 2026, emphasizing late-stage pipeline assets and near-term regulatory catalysts. Management highlighted the anticipated FDA decision on the high-dose SPINRAZA filing in April and reiterated plans to submit data for its investigational Alzheimer’s candidate by mid-year. The company reported 2025 revenue growth of 3% year-over-year, driven primarily by core neurology portfolio performance and expanding patient access programs in Europe and Asia. Biogen also discussed ongoing Phase 3 trials for its Duchenne muscular dystrophy program, noting enrollment of over 120 patients across 60 sites, with top-line data expected in Q4 2026. The presentation underscored a commitment to margin expansion, targeting adjusted operating margins north of 40% by 2027 through cost efficiencies and portfolio optimization.

In its latest SEC filing, Cerity Partners LLC disclosed a 76.7% increase in its Biogen shareholding during the third quarter, acquiring an additional 35,696 shares to reach 82,248 shares total. This stake represents approximately 0.06% of Biogen’s outstanding shares. Other institutional moves include Banque Pictet & Cie SA boosting its position by 5.5% (now 72,025 shares) and Generali Investments CEE raising its stake by 43.2% (38,755 shares). Privium Fund Management B.V. added a new position valued at roughly $2.7 million, while Nordea Investment Management AB expanded its holdings by 5.7% (125,935 shares). These reallocations reflect growing institutional confidence in Biogen’s neurology franchise and upcoming regulatory milestones.